PostEra codevelopment deal with NeuroLucent for Alzheimer’s disease
Posted on28 Nov 2020
Comments0
Biotechnology company PostEra announced a collaboration with NeuroLucent, a Chicago-based company focused on developing novel treatments for Alzheimer’s disease and other dementias.... Read More
Sobrera, Recipharm Collaborate to Advance Alcohol Use Disorder Treatment
Sobrera Pharma, and Recipharm have entered into an agreement for the formulation development and manufacturing of SO-001, a new oral treatment for... Read More
AstraZeneca, Accent Therapeutics partners to develop transformative therapeutics targeting RMPs to treat cancer
Accent Therapeutics and AstraZeneca forged a collaboration valued at about $1.1 billion to discover, develop and commercialize transformative therapeutics targeting RNA-modifying proteins... Read More
Global Licensing Agreement Case study: ProThera Biologics and Takeda to Develop Novel Plasma-Derived Therapy Based on Inter-alpha Inhibitor Proteins (IAIP)
Posted on24 Apr 2020
Comments0
ProThera Biologics, Inc. and Takeda Pharmaceutical Company Limited have entered into a global licensing agreement to develop a novel plasma-derived Inter-alpha Inhibitor... Read More
AstraZeneca and Silence Therapeutics co-development siRNA therapeutics
AstraZeneca will collaborate with Silence Therapeutics to discover, develop and commercialise small interfering RNA (siRNA) therapeutics for the treatment of cardiovascular (CV),... Read More
Prometheus Biosciences collaboration deal with Takeda for targeted therapies for IBD
Posted on06 Oct 2019
Tagscodevelopment deal in pharma, pharma strategic deal, Prometheus Biosciences, Strategic deal in pharma, Takeda
Comments0
Prometheus Biosciences, Inc, a biopharmaceutical company, has entered into a global, multi-target strategic collaboration with Takeda Pharmaceutical Company Limited (Takeda) to discover,... Read More
Case Study: Gilead and Galapagos – R&D collaboration
Posted on15 Jul 2019
Comments0
Gilead Sciences, Inc. and Galapagos NV have entered into a 10-year global research and development collaboration. Through this agreement, Gilead will gain... Read More
Secarna enters co-development pact with MetP Pharma for transnasally delivered antisense oligonucleotide-based CNS therapeutics
Secarna Pharmaceuticals (Secarna), a new breed of biopharmaceutical company, has entered into a co-development agreement with MetP Pharma (MetP), a privately held... Read More
Case Study – Quick Look up at DCGI approval of Lundbeck’s Brintellix
Posted on15 Oct 2018
TagsBrintellix, CDSCO, codevelopment deal in pharma, comarketing deal in pharma, copromotion deal in pharma, DCGI, Lundbeck, vortioxetine
Comments0
Lundbeck India Private Limited (LIPL) announces the launch of Brintellix (vortioxetine) in India for the treatment of patients suffering from major depressive... Read More
Samsung Bioepis and Takeda’s Co-development deal for novel biologics
Korean biosimilars manufacturer Samsung Bioepis Co Ltd. will team up with Japanese drugmaker Takeda Pharmaceutical Company to jointly develop new biologic therapies.... Read More